Helfrich B - Search Results

1

Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G alpha 16.

Heasley LE, Zamarripa J, Storey B, Helfrich B, Mitchell FM, Bunn PA Jr, Johnson GL. Heasley LE, et al. Among authors: helfrich b. J Biol Chem. 1996 Jan 5;271(1):349-54. doi: 10.1074/jbc.271.1.349. J Biol Chem. 1996. PMID: 8550585 Free article.

2

Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth.

Beekman A, Helfrich B, Bunn PA Jr, Heasley LE. Beekman A, et al. Among authors: helfrich b. Cancer Res. 1998 Mar 1;58(5):910-3. Cancer Res. 1998. PMID: 9500449

3

Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.

Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC. Soriano AF, et al. Among authors: helfrich b. Cancer Res. 1999 Dec 15;59(24):6178-84. Cancer Res. 1999. PMID: 10626810

4

Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism.

Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, Baron A, Yang J, Puck T, Bunn P Jr. Chan D, et al. Among authors: helfrich b. Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4608-13. doi: 10.1073/pnas.072077299. Proc Natl Acad Sci U S A. 2002. PMID: 11930011 Free PMC article.

5

Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.

Chan DC, Gera L, Stewart JM, Helfrich B, Zhao TL, Feng WY, Chan KK, Covey JM, Bunn PA Jr. Chan DC, et al. Among authors: helfrich b. Clin Cancer Res. 2002 May;8(5):1280-7. Clin Cancer Res. 2002. PMID: 12006549

6

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

Hirsch FR, Helfrich B, Franklin WA, Varella-Garcia M, Chan DC, Bunn PA Jr. Hirsch FR, et al. Among authors: helfrich b. Clin Breast Cancer. 2002 May;3 Suppl 1:12-6. doi: 10.3816/cbc.2002.s.003. Clin Breast Cancer. 2002. PMID: 12057039 Review.

7

Epidermal growth factor receptor family in lung cancer and premalignancy.

Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr. Franklin WA, et al. Semin Oncol. 2002 Feb;29(1 Suppl 4):3-14. doi: 10.1053/sonc.2002.31520. Semin Oncol. 2002. PMID: 11894009 Review.

8

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.

Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr. Raben D, et al. Semin Oncol. 2002 Feb;29(1 Suppl 4):37-46. doi: 10.1053/sonc.2002.31521. Semin Oncol. 2002. PMID: 11894012 Review.

9

Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA Jr. Coldren CD, et al. Mol Cancer Res. 2006 Aug;4(8):521-8. doi: 10.1158/1541-7786.MCR-06-0095. Mol Cancer Res. 2006. PMID: 16877703 Free article.

10

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.

Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA Jr, Raben D. Frederick BA, et al. Mol Cancer Ther. 2007 Jun;6(6):1683-91. doi: 10.1158/1535-7163.MCT-07-0138. Epub 2007 May 31. Mol Cancer Ther. 2007. PMID: 17541031

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters